<SEC-DOCUMENT>0001062993-21-006112.txt : 20210630
<SEC-HEADER>0001062993-21-006112.hdr.sgml : 20210630
<ACCEPTANCE-DATETIME>20210630163138
ACCESSION NUMBER:		0001062993-21-006112
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20210628
FILED AS OF DATE:		20210630
DATE AS OF CHANGE:		20210630

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			ATP Life Science Ventures, L.P.
		CENTRAL INDEX KEY:			0001593440
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38944
		FILM NUMBER:		211062327

	BUSINESS ADDRESS:	
		STREET 1:		230 PARK AVENUE, SUITE 2800
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10169
		BUSINESS PHONE:		212-468-5800

	MAIL ADDRESS:	
		STREET 1:		230 PARK AVENUE, SUITE 2800
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10169

	FORMER NAME:	
		FORMER CONFORMED NAME:	Apple Tree Partners IV, L.P.
		DATE OF NAME CHANGE:	20131204

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			ATP III GP, Ltd.
		CENTRAL INDEX KEY:			0001593453
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38944
		FILM NUMBER:		211062326

	BUSINESS ADDRESS:	
		STREET 1:		230 PARK AVENUE, SUITE 2800
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10169
		BUSINESS PHONE:		212-468-5800

	MAIL ADDRESS:	
		STREET 1:		230 PARK AVENUE, SUITE 2800
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10169

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Akero Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001744659
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		601 GATEWAY BOULEVARD, SUITE 350
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-487-6488

	MAIL ADDRESS:	
		STREET 1:		601 GATEWAY BOULEVARD, SUITE 350
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<DESCRIPTION>STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2021-06-28</periodOfReport>

    <notSubjectToSection16>1</notSubjectToSection16>

    <issuer>
        <issuerCik>0001744659</issuerCik>
        <issuerName>Akero Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>AKRO</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001593440</rptOwnerCik>
            <rptOwnerName>ATP Life Science Ventures, L.P.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O APPLE TREE PARTNERS</rptOwnerStreet1>
            <rptOwnerStreet2>230 PARK AVENUE, 28TH FLOOR</rptOwnerStreet2>
            <rptOwnerCity>NEW YORK</rptOwnerCity>
            <rptOwnerState>NY</rptOwnerState>
            <rptOwnerZipCode>10169</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001593453</rptOwnerCik>
            <rptOwnerName>ATP III GP, Ltd.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O APPLE TREE PARTNERS</rptOwnerStreet1>
            <rptOwnerStreet2>230 PARK AVENUE, 28TH FLOOR</rptOwnerStreet2>
            <rptOwnerCity>NEW YORK</rptOwnerCity>
            <rptOwnerState>NY</rptOwnerState>
            <rptOwnerZipCode>10169</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2021-06-28</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>J</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>5830203</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                    <footnoteId id="F2"/>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The shares were distributed in a pro rata distribution to the limited partners of ATP Life Science Ventures, L.P. (&quot;ATP,&quot; and formerly known as Apple Tree Partners IV, L.P.).</footnote>
        <footnote id="F2">The shares were directly held by ATP. ATP III GP, Ltd. (&quot;ATP GP&quot;) is the sole general partner of ATP. Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP. ATP GP and Dr. Harrison disclaim beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Seth L. Harrison, for ATP Life Science Ventures, L.P., By: Seth L. Harrison, as director of ATP III GP, Ltd., its general partner</signatureName>
        <signatureDate>2021-06-30</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Seth L. Harrison, for ATP III GP, Ltd., By: Seth L. Harrison, director</signatureName>
        <signatureDate>2021-06-30</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
